130 related articles for article (PubMed ID: 35653615)
1. Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study.
Deodhar AA; Shiff NJ; Gong C; Hsia EC; Lo KH; Kim L; Xu S; Reveille JD
J Clin Rheumatol; 2022 Aug; 28(5):270-277. PubMed ID: 35653615
[TBL] [Abstract][Full Text] [Related]
2. Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.
Deodhar A; Shiff NJ; Gong C; Chan EKH; Hsia EC; Lo KH; Akawung A; Kim L; Xu S; Reveille JD
Rheumatol Ther; 2023 Aug; 10(4):983-999. PubMed ID: 37322274
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
Deodhar A; Reveille JD; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
J Rheumatol; 2018 Mar; 45(3):341-348. PubMed ID: 29247154
[TBL] [Abstract][Full Text] [Related]
5. Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.
Gensler LS; Chakravarty SD; Cameron C; Peterson S; Spin P; Kafka S; Nair S; Deodhar A
Clin Rheumatol; 2020 Oct; 39(10):2907-2917. PubMed ID: 32367407
[TBL] [Abstract][Full Text] [Related]
6. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
Reveille JD; Hwang MC; Danve A; Kafka S; Peterson S; Lo KH; Kim L; Hsia EC; Chan EKH; Deodhar A
Clin Rheumatol; 2021 Apr; 40(4):1331-1341. PubMed ID: 32926247
[TBL] [Abstract][Full Text] [Related]
7. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C;
J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
Sieper J; van der Heijde D; Dougados M; Maksymowych WP; Scott BB; Boice JA; Berd Y; Bergman G; Curtis S; Tzontcheva A; Huyck S; Weng HH
Arthritis Rheumatol; 2015 Oct; 67(10):2702-12. PubMed ID: 26139307
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
Bao C; Huang F; Khan MA; Fei K; Wu Z; Han C; Hsia EC
Rheumatology (Oxford); 2014 Sep; 53(9):1654-63. PubMed ID: 24729398
[TBL] [Abstract][Full Text] [Related]
10. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
Deodhar A; Braun J; Inman RD; van der Heijde D; Zhou Y; Xu S; Han C; Hsu B
Ann Rheum Dis; 2015 Apr; 74(4):757-61. PubMed ID: 25387477
[TBL] [Abstract][Full Text] [Related]
11. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.
Braun J; Deodhar A; Inman RD; van der Heijde D; Mack M; Xu S; Hsu B
Ann Rheum Dis; 2012 May; 71(5):661-7. PubMed ID: 22012970
[TBL] [Abstract][Full Text] [Related]
12. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
Reveille JD; Deodhar A; Ince A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Xu S; Harrison DD; Han C
Value Health; 2020 Oct; 23(10):1281-1285. PubMed ID: 33032770
[TBL] [Abstract][Full Text] [Related]
13. [The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis].
Ma H; Sun F; Zhang YM; Zhang H; Zhu J; Deng XH; Zhang JL; Huang F
Zhonghua Nei Ke Za Zhi; 2017 Dec; 56(12):935-939. PubMed ID: 29202535
[No Abstract] [Full Text] [Related]
14. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
Inman RD; Davis JC; Heijde Dv; Diekman L; Sieper J; Kim SI; Mack M; Han J; Visvanathan S; Xu Z; Hsu B; Beutler A; Braun J
Arthritis Rheum; 2008 Nov; 58(11):3402-12. PubMed ID: 18975305
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
[TBL] [Abstract][Full Text] [Related]
17. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A
Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH
Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
Paramarta JE; De Rycke L; Heijda TF; Ambarus CA; Vos K; Dinant HJ; Tak PP; Baeten DL
Ann Rheum Dis; 2013 Nov; 72(11):1793-9. PubMed ID: 23139265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
